← Leaderboards
Adam S Kibel
Washington University
$9,755,501
Attributed
$21,206,790
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,206,790 · 7
By mechanism
UG1$7,630,727 · 1
U10$6,185,447 · 1
R01$4,554,851 · 2
U01$1,922,720 · 1
K08$607,045 · 1
R21$306,000 · 1
Top collaborators
- Harold John Burstein12 shared
- David P Ryan12 shared
- Nobuhiko Hata5 shared
- Oliver Jonas5 shared
Most similar at Washington University
Same institution · by research overlap
- Gerald Louis Andriole$6,419,713
- Hing Hung Henry Lai$7,168,350
- Samuel Klein$33,055,933
- Kristin Guilliams$4,081,995
- Siobhan Sutcliffe$5,834,302
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsWomanHospitalsEnsureMalignant Neoplasm Of ProstateClinical ResearchCancer CareResearch PersonnelInstitutionOncologyMedicalCancer PatientProstateInnovationFutureFundingTranslationsPositioning AttributeProgramsTrial DesignPilot ProjectsImageOperative Surgical Procedures
Grant awards (33)
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,048,779
UG1 · FY2025 · CA
Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer$707,952
U01 · FY2025 · CA · contact PI
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,048,778
UG1 · FY2024 · CA
Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer$674,729
U01 · FY2024 · CA · contact PI
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,106,459
UG1 · FY2023 · CA
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$658,228
R01 · FY2023 · CA
Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer$540,039
U01 · FY2023 · CA · contact PI
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,109,082
UG1 · FY2022 · CA
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$667,356
R01 · FY2022 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,109,810
UG1 · FY2021 · CA
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$686,566
R01 · FY2021 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,103,826
UG1 · FY2020 · CA
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$675,388
R01 · FY2020 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,103,993
UG1 · FY2019 · CA
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$673,221
R01 · FY2019 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,302,199
U10 · FY2018 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,302,199
U10 · FY2017 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,106,869
U10 · FY2016 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,171,980
U10 · FY2015 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care$1,302,200
U10 · FY2014 · CA
Cell Cycle Variants and Metastatic Prostate Cancer Risk$229,214
R01 · FY2009 · CA · contact PI
Cell Cycle Variants and Metastatic Prostate Cancer Risk$229,214
R01 · FY2008 · CA · contact PI
Cell Cycle Variants and Metastatic Prostate Cancer Risk$257,865
R01 · FY2007 · CA · contact PI
Cell Cycle Variants and Metastatic Prostate Cancer Risk$236,059
R01 · FY2006 · CA · contact PI
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE$48,457
K08 · FY2006 · CA · contact PI
Cell Cycle Variants and Metastatic Prostate Cancer Risk$241,740
R01 · FY2005 · CA
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE$121,537
K08 · FY2005 · CA
Genetic Risk Profiling in Metastatic Prostate Carcinoma$153,000
R21 · FY2004 · CA
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE$121,537
K08 · FY2004 · CA
Genetic Risk Profiling in Metastatic Prostate Carcinoma$153,000
R21 · FY2003 · CA
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE$121,537
K08 · FY2003 · CA
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE$72,840
K08 · FY2002 · CA
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE$121,137
K08 · FY2001 · CA